Fcγ receptor heterogeneity in leukocyte functional responses

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Rosales, Carlos ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antibody; ERK; Immunoglobulin; Integrin; Neutrophil; NF B; Phagocytosis

Indexed keywords

DIACYLGLYCEROL KINASE; FC RECEPTOR; FC RECEPTOR IIB; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C GAMMA; PHOSPHOLIPASE C GAMMA1; TRANSFORMING GROWTH FACTOR BETA;

BACTERIAL INFECTION; BINDING AFFINITY; CYTOTOXICITY; DISEASE PREDISPOSITION; FUNCTIONAL ASSESSMENT; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GLYCOSYLATION AND DEGLYCOSYLATION; HUMAN; IMMUNE SYSTEM; LEUKOCYTE ACTIVATION; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 85017222302     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00280     Document Type: Review

References (163)

1. Ballow M. Historical perspectives in the diagnosis and treatment of primary immune deficiencies. Clin Rev Allergy Immunol (2014) 46:101-3. doi:10.1007/s12016-013-8384-9
2. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol (2006) 6:231-43. doi:10.1038/nri1783
3. Tohyama Y, Yamamura H. Complement-mediated phagocytosis-the role of Syk. IUBMB Life (2006) 58:304-8. doi:10.1080/15216540600746377
4. Rosales C. Fc receptor and integrin signaling in phagocytes. Signal Transduct (2007) 7:386-401. doi:10.1002/sita.200700141
5. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol (2000) 18:709-37. doi:10.1146/annurev.immunol.18.1.709
6. Nimmerjahn F, Ravetch J. Antibodies, Fc receptors and cancer. Curr Opin Immunol (2007) 19:239-45. doi:10.1016/j.coi.2007.01.005
7. Powell MS, Hogarth PM. Fc receptors. Adv Exp Med Biol (2008) 640:22-34. doi:10.1007/978-0-387-09789-3_3
8. Rosales C, Uribe-Querol E. Antibody-Fc receptor interactions in antimicrobial functions. Curr Immunol Rev (2013) 9:44-55. doi:10.2174/1573395511309010006
9. Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol (2011) 350:105-25. doi:10.1007/82_2010_86
10. Sondermann P. The FcγR/IgG interaction as target for the treatment of autoimmune diseases. J Clin Immunol (2016) 36:95-9. doi:10.1007/s10875-016-0272-7
11. Yu X, Lazarus AH. Targeting FcγRs to treat antibody-dependent autoimmunity. Autoimmun Rev (2016) 15:510-2. doi:10.1016/j.autrev.2016.02.006
12. Sondermann P, Szymkowski DE. Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr Opin Immunol (2016) 40:78-87. doi:10.1016/j.coi.2016.03.005
13. Nimmerjahn F, Ravetch J. Fcγ receptors: old friends and new family members. Immunity (2006) 24:19-28. doi:10.1016/j.immuni.2005.11.010
14. Rosales C, Uribe-Querol E. Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol (2013) 4:21-33. doi:10.4236/abb.2013.44A004
15. Arnold J, Wormald M, Sim R, Rudd P, Dwek R. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 25:21-50. doi:10.1146/annurev.immunol.25.022106.141702
16. Raju T. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 20:471-8. doi:10.1016/j.coi.2008.06.007
17. Anthony RM, Wermeling F, Ravetch JV. Novel roles of the IgG Fc glycan. Ann N Y Acad Sci (2012) 1253:170-80. doi:10.1111/j.1749-6632.2011.06305.x
18. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood (2012) 119:5640-9. doi:10.1182/blood-2012-01-380121
19. Mancardi D, Iannascoli B, Hoos S, England P, Daëron M, Bruhns P. FcγRIV is a mouse IgE receptor that resembles macrophage FceRI in humans and promotes IgE-induced lung inflammation. J Clin Invest (2008) 118:3738-50. doi:10.1172/JCI36452
20. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7:715-25. doi:10.1038/nri2155
21. Stapleton NM, Einarsdóttir HK, Stemerding AM, Vidarsson G. The multiple facets of FcRn in immunity. Immunol Rev (2015) 268:253-68. doi:10.1111/imr.12331
22. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A (2010) 107:9985-19990. doi:10.1073/pnas.1014074107
23. Foss S, Watkinson R, Sandlie I, James LC, Andersen JT. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev (2015) 268:328-39. doi:10.1111/imr.12363
24. Bruhns P, Jönsson F. Mouse and human FcR effector functions. Immunol Rev (2015) 268:25-51. doi:10.1111/imr.12350
25. Daëron M. Fc receptor biology. Annu Rev Immunol (1997) 15:203-34. doi:10.1146/annurev.immunol.15.1.203
26. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol (2001) 19:275-90. doi:10.1146/annurev.immunol.19.1.275
27. Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol (2012) 188:4741-5. doi:10.4049/jimmunol.1102651
28. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity (2001) 14:277-89. doi:10.1016/S1074-7613(01)00109-1
29. Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, et al. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood (2003) 102:3684-92. doi:10.1182/blood-2003-03-0750
30. Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med (2005) 202:783-91. doi:10.1084/jem.20050879
31. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 20:769-83. doi:10.1016/j.immuni.2004.05.007
32. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol (2001) 166:3266-76. doi:10.4049/jimmunol.166.5.3266
33. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood (2006) 108:3573-9. doi:10.1182/blood-2006-05-024539
34. Ravetch JV. Fc receptors. 5th ed. In: Paul WE, editor. Fundamental Immunology. Philadelphia, PA: Lippincott Williams and Wilkins (2003). p. 631-84.
35. Bruhns P, Iannascoli B, England P, Mancardi D, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113:3716-25. doi:10.1182/blood-2008-09-179754
36. Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol (2007) 28:66-73. doi:10.1016/j.it.2006.12.004
37. Daëron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv Immunol (2006) 89:39-86. doi:10.1016/S0065-2776(05)89002-9
38. Stefanescu RN, Olferiev M, Liu Y, Pricop L. Inhibitory Fcγ receptors: from gene to disease. J Clin Immnol (2004) 24:315-26. doi:10.1023/B:JOCI.0000029105.47772.04
39. Baerenwaldt A, Nimmerjahn F. Immune regulation: FcγRIIB-regulating the balance between protective and autoreactive immune responses. Immunol Cell Biol (2008) 86:482-4. doi:10.1038/icb.2008.34
40. Boruchov A, Heller G, Veri M, Bonvini E, Ravetch J, Young J. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 115:2914-23. doi:10.1172/JCI24772
41. Nimmerjahn F, Ravetch J. Fcγ receptors as regulators of immune responses. Nat Rev Immunol (2008) 8:34-47. doi:10.1038/nri2206
42. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev (2010) 236:265-75. doi:10.1111/j.1600-065X.2010.00910.x
43. Lehmann B, Schwab I, Böhm S, Lux A, Biburger M, Nimmerjahn F. FcγRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol (2012) 8:243-54. doi:10.1586/eci.12.5
44. Meknache N, Jönsson F, Laurent J, Guinnepain MT, Daëron M. Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor FcγRIIIB (CD16B). J Immunol (2009) 182:2542-50. doi:10.4049/jimmunol.0801665
45. Willcocks LC, Smith KG, Clatworthy MR. Low-affinity Fcγ receptors, autoimmunity and infection. Expert Rev Mol Med (2009) 11:e24. doi:10.1017/S1462399409001161
46. van Sorge NM, van der Pol WL, van de Winkel JG. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens (2003) 61:189-202. doi:10.1034/j.1399-0039.2003.00037.x
47. Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J Exp Med (1990) 172:19-25. doi:10.1084/jem.172.1.19
48. Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human FcγRIIA determined with allele specific oligonucleotide probes. J Immunol Methods (1994) 173:207-17. doi:10.1016/0022-1759(94)90299-2
49. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest (1997) 100:1059-70. doi:10.1172/JCI119616
50. Koene HR, Kleijer M, Swaak AJG, Sullivan KE, Bijl M, Petri MA, et al. The FcγRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum (1998) 41:1813-8. doi:10.1002/1529-0131(199810)41:10<1813::AID-ART13>3.3.CO;2-Y
51. Huizinga TWJ, Kleijer M, Tetteroo PAT, Roos D, von dem Borne AE. Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16). Blood (1990) 75:213-7.
52. Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 84:1688-91. doi:10.1172/JCI114350
53. Salmon JE, Edberg JC, Kimberly RP. Fcγ receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest (1990) 85:1287-95. doi:10.1172/JCI114566
54. Hatta Y, Tsuchiya N, Ohashi J, Matsushita M, Fujiwara K, Hagiwara K, et al. Association of Fcγ receptor IIIB, but not of Fcγ receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese. Genes Immun (1999) 1:53-60. doi:10.1038/sj.gene.6363639
55. Bux J, Stein E-L, Bierling P, Fromont P, Clay M, Stroncek D, et al. Characterization of a new alloantigen (SH) on the human neutrophil Fcγ receptor IIIB. Blood (1997) 89:1027-34.
56. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature (2006) 439:851-5. doi:10.1038/nature04489
57. Duits AJ, Bootsma H, Derksen RH, Spronk PE, Kater L, Kallenberg CG, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 38:1832-6. doi:10.1002/art.1780381217
58. Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, de Haas M, Capel PJ, et al. Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis (1994) 170:854-61. doi:10.1093/infdis/170.4.854
59. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. Blood (1999) 94:4220-32.
60. Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J. Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum (2000) 43:735-9. doi:10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q
61. Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, et al. Analysis of FcγRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet (1997) 14:183-95.
62. Tse WY, Abadeh S, Jefferis R, Savage CO, Adu D. Neutrophil FcγRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol (2000) 119:574-7. doi:10.1046/j.1365-2249.2000.01182.x
63. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol (1991) 9:457-92. doi:10.1146/annurev.iy.09.040191.002325
64. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: up-regulation by IFN-γ. J Immunol (2000) 164:4332-9. doi:10.4049/jimmunol.164.8.4332
65. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology (2007) 121:392-404. doi:10.1111/j.1365-2567.2007.02588.x
66. Cassard L, Jönsson F, Arnaud S, Daëron M. Fcγ receptors inhibit mouse and human basophil activation. J Immunol (2012) 189:2995-3006. doi:10.4049/jimmunol.1200968
67. Magnusson SE, Engström M, Jacob U, Ulfgren AK, Kleinau S. High synovial expression of the inhibitory FcγRIIb in rheumatoid arthritis. Arthritis Res Ther (2007) 9:R51. doi:10.1186/ar2206
68. Anderson CL, Ganesan LP, Robinson JM. The biology of the classical Fcγ receptors in non-hematopoietic cells. Immunol Rev (2015) 268:236-40. doi:10.1111/imr.12335
69. Mohamed HA, Mosier DR, Zou LL, Siklós L, Alexianu ME, Engelhardt JI, et al. Immunoglobulin Fcγ receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res (2002) 69:110-6. doi:10.1002/jnr.10271
70. Nakamura K, Hirai H, Torashima T, Miyazaki T, Tsurui H, Xiu Y, et al. CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. Mol Cell Biol (2007) 27:5128-34. doi:10.1128/MCB.01072-06
71. Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, et al. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol (2012) 189:4981-8. doi:10.4049/jimmunol.1202017
72. Pricop L, Redecha P, Teillaud J-L, Frey J, Fridman WH, Sautès-Fridman C, et al. Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 166:531-7. doi:10.4049/jimmunol.166.1.531
73. Schmidt R, Gessner J. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett (2005) 100:56-67. doi:10.1016/j.imlet.2005.06.022
74. Tridandapani S, Wardrop R, Baran CP, Wang Y, Opalek JM, Caligiuri MA, et al. TGF-β1 suppresses myeloid Fcγ receptor function by regulating the expression and function of the common γ-subunit. J Immunol (2003) 170:4572-7. doi:10.4049/jimmunol.170.9.4572
75. Lynch A, Tartour E, Teillaud JL, Asselain B, Fridman WH, Sautès C. Increased levels of soluble low-affinity Fc gamma receptors (IgG-binding factors) in the sera of tumour-bearing mice. Clin Exp Immunol (1992) 87:208-14. doi:10.1111/j.1365-2249.1992.tb02976.x
76. Rappaport EF, Cassel DL, Walterhouse DO, McKenzie SE, Surrey S, Keller MA, et al. A soluble form of the human Fc receptor Fc gamma RIIA: cloning, transcript analysis and detection. Exp Hematol (1993) 21:689-96.
77. Sautès C, Teillaud C, Mazières N, Tartour E, Bouchard C, Galinha A, et al. Soluble Fc gamma R (sFc gamma R): detection in biological fluids and production of a murine recombinant sFc gamma R biologically active in vitro and in vivo. Immunobiology (1992) 185:207-21. doi:10.1016/S0171-2985(11)80642-X
78. Teillaud JL, Bouchard C, Astier A, Teillaud C, Tartour E, Michon J, et al. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. Immunomethods (1994) 4:48-64. doi:10.1006/immu.1994.1007
79. Fridman WH, Teillaud JL, Bouchard C, Teillaud C, Astier A, Tartour E, et al. Soluble Fc gamma receptors. J Leukoc Biol (1993) 54:504-12.
80. Sautès C, Varin N, Teillaud C, Daëron M, Even J, Hogarth PM, et al. Soluble Fc γ receptors II (Fc γ RII) are generated by cleavage of membrane Fc γ RII. Eur J Immunol (1991) 21:231-4. doi:10.1002/eji.1830210135
81. Sautès C, Mazières N, Galinha A, Tartour E, Bonnerot C, Amigorena S, et al. Murine soluble Fc gamma receptors/IgG-binding factors (IgG-BF): analysis of the relation to Fc gamma RII and production of milligram quantities of biologically active recombinant IgG-BF. Immunol Res (1992) 11:181-90. doi:10.1007/BF02919125
82. Tartour E, de la Salle H, de la Salle C, Teillaud C, Camoin L, Galinha A, et al. Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fc gamma R) encoded by an alternatively spliced transcript of the Fc gamma RII gene. Int Immunol (1993) 5:859-68. doi:10.1093/intimm/5.8.859
83. Fridman WH, Bonnerot C, Daeron M, Amigorena S, Teillaud JL, Sautes C. Structural bases of Fc gamma receptor functions. Immunol Rev (1992) 125:49-76. doi:10.1111/j.1600-065X.1992.tb00625.x
84. Esposito-Farese ME, Sautès C, de la Salle H, Latour S, Bieber T, de la Salle C, et al. Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol (1995) 155:1725-36.
85. Astier A, de la Salle H, Moncuit J, Freund M, Cazenave JP, Fridman WH, et al. Detection and quantification of secreted soluble Fc gamma RIIA in human sera by an enzyme-linked immunosorbent assay. J Immunol Methods (1993) 166:1-10. doi:10.1016/0022-1759(93)90323-Y
86. de la Salle C, Esposito-Farese ME, Bieber T, Moncuit J, Morales M, Wollenberg A, et al. Release of soluble Fc gamma RII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Invest Dermatol (1992) 99:15S-7S. doi:10.1111/1523-1747.ep12668250
87. Sármay G, Rozsnyay Z, Gergely J. Fc gamma RII expression and release on resting and activated human B lymphocytes. Mol Immunol (1990) 27:1195-200. doi:10.1016/0161-5890(90)90022-R
88. Gergely J, Sarmay G. B-cell activation-induced phosphorylation of Fc gamma RII: a possible prerequisite of proteolytic receptor release. Immunol Rev (1992) 125:5-19. doi:10.1111/j.1600-065X.1992.tb00622.x
89. Lanier LL, Phillips JH, Testi R. Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes. Eur J Immunol (1989) 19:775-8. doi:10.1002/eji.1830190431
90. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol (1991) 147:3459-65.
91. Huizinga TW, van der Schoot CE, Jost C, Klaassen R, Kleijer M, von dem Borne AE, et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature (1988) 333:667-9. doi:10.1038/333667a0
92. Huizinga TW, de Haas M, Kleijer M, Nuijens JH, Roos D, von dem Borne AE. Soluble Fc gamma receptor III in human plasma originates from release by neutrophils. J Clin Invest (1990) 86:416-23. doi:10.1172/JCI114727
93. Mota G, Moldovan I, Calugaru A, Hirt M, Kozma E, Galatiuc C, et al. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing. Scand J Immunol (2004) 59:278-84. doi:10.1111/j.0300-9475.2004.01398.x
94. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol (1994) 152:1314-22.
95. Galon J, Moldovan I, Galinha A, Provost-Marloie MA, Kaudewitz H, Roman-Roman S, et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol (1998) 28:2101-7. doi:10.1002/(SICI)1521-4141(199807)28:07<2101::AID-IMMU2101>3.0.CO;2-W
96. Middelhoven PJ, Van Buul JD, Hordijk PL, Roos D. Different proteolytic mechanisms involved in Fc gamma RIIIb shedding from human neutrophils. Clin Exp Immunol (2001) 125:169-75. doi:10.1046/j.1365-2249.2001.01548.x
97. Wang Y, Wu J, Newton R, Bahaie NS, Long C, Walcheck B. ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils. Biochim Biophys Acta (2013) 1833:680-5. doi:10.1016/j.bbamcr.2012.11.027
98. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood (2013) 121:3599-608. doi:10.1182/blood-2012-04-425397
99. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 19:3844-55. doi:10.1158/1078-0432.CCR-13-0505
100. Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, et al. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol (2014) 192:741-51. doi:10.4049/jimmunol.1301024
101. Peruzzi G, Femnou L, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, et al. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol (2013) 191:1883-94. doi:10.4049/jimmunol.1300313
102. Jing Y, Ni Z, Wu J, Higgins L, Markowski TW, Kaufman DS, et al. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One (2015) 10:e0121788. doi:10.1371/journal.pone.0121788
103. Daëron M, Sautès C, Bonnerot C, Blank U, Varin N, Even J, et al. Murine type II Fc gamma receptors and IgG-binding factors. Chem Immunol (1989) 47:21-78. doi:10.1159/000318912
104. Bouchard C, Galinha A, Tartour E, Fridman WH, Sautès C. A transforming growth factor beta-like immunosuppressive factor in immunoglobulin G-binding factor. J Exp Med (1995) 182:1717-26. doi:10.1084/jem.182.6.1717
105. Teillaud C, Galon J, Zilber MT, Mazières N, Spagnoli R, Kurrle R, et al. Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses. Blood (1993) 82:3081-90.
106. Selvaraj P, Rosse WF, Silber R, Springer TA. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 333:565-7. doi:10.1038/333565a0
107. Moldovan I, Galon J, Maridonneau-Parini I, Roman Roman S, Mathiot C, Fridman WH, et al. Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunol Lett (1999) 68:125-34. doi:10.1016/S0165-2478(99)00041-3
108. Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol (2010) 6:425-34. doi:10.1586/eci.10.9
109. Jolles S, Kaveri SV, Orange J. Intravenous immunoglobulins. Current understanding and future directions. Clin Exp Immunol (2011) 158:68-70. doi:10.1111/j.1365-2249.2009.04029.x
110. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 342:945-9. doi:10.1016/0140-6736(93)92000-J
111. Khayat D, Soubrane C, Andrieu JM, Visonneau S, Eme D, Tourani JM, et al. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis (1990) 161:430-5. doi:10.1093/infdis/161.3.430
112. Tang CC, Isitman G, Bruneau J, Tremblay C, Bernard NF, Kent SJ, et al. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clin Exp Immunol (2015) 181:275-85. doi:10.1111/cei.12593
113. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol (2010) 125:S41-52. doi:10.1016/j.jaci.2009.09.046
114. Uchida J, Hamaguchi Y, Oliver J, Ravetch J, Poe J, Haas K, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 199:1659-69. doi:10.1084/jem.20040119
115. Lambert S, Okada C, Levy R. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J Immunol (2004) 172:929-36. doi:10.4049/jimmunol.172.2.929
116. Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an anti-erythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J Exp Med (2000) 191:1293-302. doi:10.1084/jem.191.8.1293
117. Nimmerjahn F, Ravetch J. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science (2005) 310:1510-2. doi:10.1126/science.1118948
118. Giorgini A, Brown HJ, Lock HR, Nimmerjahn F, Ravetch JV, Verbeek JS, et al. FcγRIII and FcγRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 181:8745-52. doi:10.4049/jimmunol.181.12.8745
119. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch J. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 23:41-51. doi:10.1016/j.immuni.2005.05.010
120. Meyer D, Schiller C, Westermann J, Izui S, Hazenbos W, Verbeek J, et al. FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood (1998) 92:3997-4002.
121. Concetti F, Napolioni V. Insights into the role of Fc gamma receptors (FcγRs) genetic variations in monoclonal antibody-based anti-cancer therapy. Recent Pat Anticancer Drug Discov (2010) 5:97-204. doi:10.2174/157489210791760490
122. Kim JM, Ashkenazi A. Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med (2013) 210:1647-51. doi:10.1084/jem.20131625
123. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol (1997) 15:26-32. doi:10.1016/S0167-7799(96)10062-7
124. Shields R, Namenuk A, Hong K, Meng Y, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem (2001) 276:6591-604. doi:10.1074/jbc.M009483200
125. Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes in immunoglobulin G oligosaccharides with age in healthy human serum. Glucoconj J (1997) 14:401-5. doi:10.1023/A:1018582930906
126. Mizuochi T, Hamako J, Nose M, Titani K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J Immunol (1990) 145:1794-8.
127. Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 313:670-3. doi:10.1126/science.1129594
128. Rook G, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun (1991) 4:779-94. doi:10.1016/0896-8411(91)90173-A
129. van de Geijn F, Wuhrer M, Selman M, Willemsen S, de Man Y, Deelder A, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther (2009) 11:R193. doi:10.1186/ar2892
130. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 8:226-34. doi:10.1038/nrd2804
131. Mizuochi T, Taniguchi T, Shimitzu A, Kobata A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol (1982) 129:2016-20.
132. Shields R, Lai J, Keck R, O'Connell L, Hong K, Meng Y, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 277:26733-40. doi:10.1074/jbc.M202069200
133. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2003) 278:3466-73. doi:10.1074/jbc.M210665200
134. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci (2009) 100:1566-72. doi:10.1111/j.1349-7006.2009.01222.x
135. Varki A. "Unusual" modifications and variations of vertebrate oligosaccharides: are we missing the flowers from the trees? Glycobiology (1996) 6:707-10. doi:10.1093/glycob/6.7.707
136. Scallon B, Tam S, McCarthy S, Cai A, Raju T. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol (2007) 44:1524-32. doi:10.1016/j.molimm.2006.09.005
137. Anthony R, Nimmerjahn F, Ashline D, Reinhold V, Paulson J, Ravetch J. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 320:373-6. doi:10.1126/science.1154315
138. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immnol (2010) 30:S9-14. doi:10.1007/s108575-010-9405-6
139. Bournazos S, Ravetch JV. Fcγ receptor pathways during active and passive immunization. Immunol Rev (2015) 268:88-103. doi:10.1111/imr.12343
140. Sánchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol (1998) 63:521-33.
141. Mócsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med (2013) 210:1283-99. doi:10.1084/jem.20122220
142. Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res (2015) 2015:983698. doi:10.1155/2015/983698
143. Ortiz-Stern A, Rosales C. FcgRIIIB stimulation promotes b1 integrin activation in human neutrophils. J Leukoc Biol (2005) 77:787-99. doi:10.1189/jlb.0504310
144. García-García E, Nieto-Castañeda G, Ruiz-Saldaña M, Mora N, Rosales C. FcγRIIA and FcγRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. J Immunol (2009) 182:4547-56. doi:10.4049/jimmunol.0801468
145. Rivas-Fuentes S, García-García E, Nieto-Castañeda G, Rosales C. Fcγ receptors exhibit different phagocytosis potential in human neutrophils. Cell Immunol (2010) 263:114-21. doi:10.1016/j.cellimm.2010.03.006
146. García-García E, Uribe-Querol E, Rosales C. A simple and efficient method to detect nuclear factor activation in human neutrophils by flow cytometry. J Vis Exp (2013) 74:e50410. doi:10.3791/50410
147. Alemán OR, Mora N, Cortes-Vieyra R, Uribe-Querol E, Rosales C. Differential use of human neutrophil Fcγ receptors for inducing neutrophil extracellular trap formation. J Immunol Res (2016) 2016:142643. doi:10.1155/2016/2908034
148. Salmon JE, Browle NL, Edberg JC, Kimberly RP. Fcg receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fcg receptor II. J Immunol (1991) 146:997-1004.
149. Kocher M, Siegel ME, Edberg JC, Kimberly RP. Cross-linking of Fcg receptor IIa and Fcg receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol (1997) 159:3940-8.
150. García-García E, Rosales C. Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol (2002) 72:1092-108.
151. García-García E, Rosales C. Fc receptor signaling in leukocytes: role in host defense and immune regulation. Curr Immunol Rev (2009) 5:227-42. doi:10.2174/157339509788921229
152. Coxon PY, Rane MJ, Powell DW, Klein JB, McLeish KR. Differential mitogen-activated protein kinase stimulation by Fc gamma receptor IIa and Fc gamma receptor IIIb determines the activation phenotype of human neutrophils. J Immunol (2000) 164:6530-7. doi:10.4049/jimmunol.164.12.6530
153. van Egmond M, Vidarsson G, Bakema JE. Cross-talk between pathogen recognizing toll-like receptors and immunoglobulin Fc receptors in immunity. Immunol Rev (2015) 268:311-27. doi:10.1111/imr.12333
154. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol (2007) 5:577-82. doi:10.1038/nrmicro1710
155. Yipp BG, Kubes P. NETosis: how vital is it? Blood (2013) 122:2784-94. doi:10.1182/blood-2013-04-457671
156. Branzk N, Papayannopoulos V. Molecular mechanisms regulating NETosis in infection and disease. Semin Immunopathol (2013) 35:513-30. doi:10.1007/s00281-013-0384-6
157. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol (2012) 198:773-83. doi:10.1083/jcb.201203170
158. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. Blood (2012) 120:4421-31. doi:10.1182/blood-2011-12-401133
159. Short KR, von Köckritz-Blickwede M, Langereis JD, Chew KY, Job ER, Armitage CW, et al. Antibodies mediate formation of neutrophil extracellular traps in the middle ear and facilitate secondary pneumococcal otitis media. Infect Immun (2014) 82:364-70. doi:10.1128/IAI.01104-13
160. Behnen M, Leschczyk C, Möller S, Batel T, Klinger M, Solbach W, et al. Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcγRIIIB and Mac-1. J Immunol (2014) 193:1954-65. doi:10.4049/jimmunol.1400478
161. Alemán OR, Mora N, Cortes-Vieyra R, Uribe-Querol E, Rosales C. Transforming growth factor-β-activated kinase 1 is required for human FcγRIIIb-induced neutrophil extracellular trap formation. Front Immunol (2016) 7:277. doi:10.3389/fimmu.2016.00277
162. Eccles SA. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res (2001) 3:86-90. doi:10.1186/bcr276
163. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 10:230-52. doi:10.1038/cmi.2013.10